INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,176,760 | -6.1% | 226,969 | +21.1% | 0.00% | 0.0% |
| Q2 2023 | $7,642,295 | +25.5% | 187,403 | +14.7% | 0.00% | 0.0% |
| Q1 2023 | $6,089,918 | +149.0% | 163,400 | +133.1% | 0.00% | +100.0% |
| Q4 2022 | $2,445,300 | -67.7% | 70,086 | -48.2% | 0.00% | -66.7% |
| Q3 2022 | $7,567,000 | +95.5% | 135,224 | +80.8% | 0.00% | +200.0% |
| Q2 2022 | $3,871,000 | -46.3% | 74,800 | -24.6% | 0.00% | -50.0% |
| Q1 2022 | $7,205,000 | -52.8% | 99,142 | -23.2% | 0.00% | -50.0% |
| Q4 2021 | $15,272,000 | -11.4% | 129,163 | +0.5% | 0.00% | 0.0% |
| Q3 2021 | $17,234,000 | -7.1% | 128,463 | +12.1% | 0.00% | 0.0% |
| Q2 2021 | $18,550,000 | +83.6% | 114,564 | -9.0% | 0.00% | +100.0% |
| Q1 2021 | $10,105,000 | +20.0% | 125,915 | -18.6% | 0.00% | 0.0% |
| Q4 2020 | $8,419,000 | +536.4% | 154,761 | +132.4% | 0.00% | – |
| Q3 2020 | $1,323,000 | -43.0% | 66,588 | -39.7% | 0.00% | -100.0% |
| Q2 2020 | $2,320,000 | +134.8% | 110,375 | +36.7% | 0.00% | – |
| Q1 2020 | $988,000 | +8.9% | 80,727 | +30.5% | 0.00% | – |
| Q4 2019 | $907,000 | +23.1% | 61,870 | +12.1% | 0.00% | – |
| Q3 2019 | $737,000 | -13.8% | 55,186 | +5.7% | 0.00% | – |
| Q2 2019 | $855,000 | +8.0% | 52,214 | +12.5% | 0.00% | – |
| Q1 2019 | $792,000 | +71.4% | 46,412 | +37.1% | 0.00% | – |
| Q4 2018 | $462,000 | -74.3% | 33,852 | -46.0% | 0.00% | -100.0% |
| Q3 2018 | $1,796,000 | -8.0% | 62,746 | -12.1% | 0.00% | 0.0% |
| Q2 2018 | $1,952,000 | +17.3% | 71,373 | -9.6% | 0.00% | – |
| Q1 2018 | $1,664,000 | +149.1% | 78,958 | +127.1% | 0.00% | – |
| Q4 2017 | $668,000 | +61.0% | 34,767 | +108.0% | 0.00% | – |
| Q3 2017 | $415,000 | -14.1% | 16,717 | -44.7% | 0.00% | – |
| Q2 2017 | $483,000 | +213.6% | 30,215 | +176.1% | 0.00% | – |
| Q1 2017 | $154,000 | +266.7% | 10,945 | +231.7% | 0.00% | – |
| Q4 2016 | $42,000 | +2.4% | 3,300 | +37.5% | 0.00% | – |
| Q3 2016 | $41,000 | -19.6% | 2,400 | 0.0% | 0.00% | – |
| Q2 2016 | $51,000 | – | 2,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |